Botswana-Harvard School of Public Health AIDS Initiative Partnership CTU

$2,382,602UM1FY2014AINIH

Harvard School Of Public Health, Boston MA

Investigators

Linked publications, trials & patents

Paper 39250651 Paper 39175843 Paper 38938873 Paper 38568956 Paper 38381407 Paper 38197863 Paper 38180851 Paper 37768207 Paper 37634517 Paper 37603217 Paper 37541705 Paper 37503623 Paper 37491747 Paper 37486775 Paper 37363917 Paper 37306344 Paper 37167996 Paper 37017075 Paper 36969345 Paper 36966617 Paper 36931242 Paper 36930628 Paper 36805331 Paper 36650479 Paper 36524872 Paper 36163664 Paper 36049028 Paper 35943252 Paper 35489377 Paper 35413022 Paper 35294524 Paper 35239624 Paper 35235653 Paper 35165682 Paper 35165216 Paper 34794178 Paper 34694878 Paper 34369424 Paper 34151439 Paper 33812487 Paper 33772550 Paper 33494754 Paper 32645160 Paper 32160827 Paper 32106141 Paper 31651545 Paper 31504342 Paper 31498109 Paper 31487271 Paper 31414121 Paper 31399793 Paper 30951600 Paper 30942853 Paper 30919881 Paper 30865794 Paper 30606316 Paper 30527329 Paper 30092866 Paper 30020964 Paper 29868833 Paper 29762690 Paper 29557855 Paper 29403482 Paper 29293156 Paper 28749822 Paper 28489856 Paper 28481902 Paper 28385131 Paper 27914856 Paper 27615375 Paper 27532476 Paper 27424812 Paper 27090986 Paper 26859828 Paper 26831472 Paper 26688534 Paper 26582887 Paper 26082504 Paper 26035319 Paper 26009832 Paper 25753401 Paper 25722197 Paper 25664336 Paper 25582793 Paper 25034889 Paper 24938526 Paper 24903939 Paper 24842909 Paper 24602844 Paper 24562349 Paper 24443547 Paper 24430455 Paper 24226057 Paper 24225757 Paper 24145879 Paper 23908493 Paper 23687295

Abstract

DESCRIPTION (provided by the applicant): This is an application to renew a clinical trials unit (CTU) in Botswana, which has the second-highest prevalence of HIV in the world but also a sympathetic and interested government. This program will engage in research related to adult HIV therapeutic strategies (including antiretroviral treatment strategies, the diagnosis/management of noninfectious co-morbidities, and the infectious co-morbidities of hepatitis and tuberculosis); strategies to address HIV and HIV-associated infections/conditions in piediatric and maternal populations; integrated HIV prevention strategies in pediatric and adult populations; and vaccines to prevent HIV infection. These activities will occur through participation in four networks: ACTG, IMPAACT, HPTN, and HVTN. The objectives are to help develop and facilitate strategies for prevention and treatment of HIV infection and HIV-related illnesses (and for HIV vaccines) that are relevant for alleviating the epidemic in sub-Saharan Africa and elsewhere. Investigators and other key personnel from the Botswana CTU will participate in and contribute to network scientific and leadership activities in all areas, including joining and potentially leading protocol teams and scientific / resource committees ofthe networks with which this CTU will be affiliated. The Botswana CTU will conduct an integrated program for clinical research that includes clinical and laboratory activities. Two established clinical research sites (in Gaborone and Molepolole) will be affiliated with this CTU, and will allow efficient enrollment of participants in both urban and village populations into trials in Botswana. The investigators and staff are highly experienced in AIDS research, including trials in all proposed research areas, and have a strong record of collaboration with national and international agencies and networks, and a substantial record of having completed trials with very high standards. The combined resources of the Botswana CTU are substantial for both facilities and personnel.

View original record on NIH RePORTER →